Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Bellevue Group AG

Bellevue Group AG cut its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,735,915 shares of the biopharmaceutical company's stock after selling 143,633 shares during the period. Agios Pharmaceuticals comprises about 2.7% of Bellevue Group AG's investment portfolio, making the stock its 12th biggest holding. Bellevue Group AG owned approximately 6.55% of Agios Pharmaceuticals worth $165,987,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter worth $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $146,000.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded up $0.73 during midday trading on Friday, reaching $59.39. 237,613 shares of the company traded hands, compared to its average volume of 729,884. The firm has a market capitalization of $3.39 billion, a price-to-earnings ratio of 5.23 and a beta of 0.75. The company has a fifty day moving average price of $48.68 and a 200 day moving average price of $45.49. Agios Pharmaceuticals, Inc. has a twelve month low of $20.96 and a twelve month high of $62.58.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Leerink Partnrs downgraded Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 27th. Raymond James restated an "outperform" rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Scotiabank lifted their price objective on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Finally, Leerink Partners cut shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $52.33.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.